PL3558369T3 - Przeciwciała specyficznie wiążące się z ludzką il-15 i ich zastosowania - Google Patents
Przeciwciała specyficznie wiążące się z ludzką il-15 i ich zastosowaniaInfo
- Publication number
- PL3558369T3 PL3558369T3 PL17883800.9T PL17883800T PL3558369T3 PL 3558369 T3 PL3558369 T3 PL 3558369T3 PL 17883800 T PL17883800 T PL 17883800T PL 3558369 T3 PL3558369 T3 PL 3558369T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- human
- specifically bind
- bind
- specifically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5443—IL-15
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437143P | 2016-12-21 | 2016-12-21 | |
| PCT/US2017/067917 WO2018119246A1 (en) | 2016-12-21 | 2017-12-21 | Antibodies that specifically bind to human il-15 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3558369T3 true PL3558369T3 (pl) | 2025-06-23 |
Family
ID=62627610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17883800.9T PL3558369T3 (pl) | 2016-12-21 | 2017-12-21 | Przeciwciała specyficznie wiążące się z ludzką il-15 i ich zastosowania |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11267883B2 (pl) |
| EP (2) | EP4585261A3 (pl) |
| JP (2) | JP7155126B2 (pl) |
| KR (2) | KR102706743B1 (pl) |
| CN (1) | CN110234349B (pl) |
| AR (1) | AR110414A1 (pl) |
| AU (2) | AU2017382850B2 (pl) |
| BR (1) | BR112019012570A8 (pl) |
| CA (1) | CA3046387A1 (pl) |
| CL (1) | CL2019001729A1 (pl) |
| DK (1) | DK3558369T3 (pl) |
| EA (1) | EA201991514A1 (pl) |
| ES (1) | ES3026508T3 (pl) |
| FI (1) | FI3558369T3 (pl) |
| HR (1) | HRP20250482T1 (pl) |
| HU (1) | HUE071878T2 (pl) |
| IL (1) | IL267113B2 (pl) |
| LT (1) | LT3558369T (pl) |
| MA (1) | MA47130B1 (pl) |
| MD (1) | MD3558369T2 (pl) |
| MX (2) | MX2019007357A (pl) |
| PE (1) | PE20191497A1 (pl) |
| PH (1) | PH12019501453A1 (pl) |
| PL (1) | PL3558369T3 (pl) |
| PT (1) | PT3558369T (pl) |
| RS (1) | RS66900B1 (pl) |
| SI (1) | SI3558369T1 (pl) |
| UA (1) | UA126284C2 (pl) |
| WO (1) | WO2018119246A1 (pl) |
| ZA (1) | ZA201903848B (pl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI707038B (zh) | 2013-08-05 | 2020-10-11 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
| WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| HK1258869A1 (zh) | 2015-09-18 | 2019-11-22 | Twist Bioscience Corporation | 寡核酸变体文库及其合成 |
| CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
| US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
| AU2017382850B2 (en) | 2016-12-21 | 2024-11-21 | Cephalon Llc | Antibodies that specifically bind to human IL-15 and uses thereof |
| US11550939B2 (en) | 2017-02-22 | 2023-01-10 | Twist Bioscience Corporation | Nucleic acid based data storage using enzymatic bioencryption |
| IL271205B2 (en) | 2017-06-12 | 2025-02-01 | Twist Bioscience Corp | Methods for assembling continuous nucleic acids |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| GB2581620A (en) | 2017-09-11 | 2020-08-26 | Twist Bioscience Corp | GPCR binding proteins and synthesis thereof |
| CA3079613A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
| GB2585506A (en) | 2018-01-04 | 2021-01-13 | Twist Bioscience Corp | DNA-based digital information storage |
| CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| JP2021530243A (ja) | 2018-07-25 | 2021-11-11 | アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. | 新規ｉｌ−２１プロドラッグおよびそれを使用する方法 |
| US11828385B2 (en) | 2018-12-25 | 2023-11-28 | Ntn Corporation | Flow control valve seal and flow control valve device |
| EP3902816A4 (en) | 2018-12-26 | 2022-09-14 | Twist Bioscience Corporation | HIGHLY ACCURATE POLYNUCLEOTIDE DE NOVO SYNTHESIS |
| AU2020227802A1 (en) | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| JP2022521551A (ja) | 2019-02-26 | 2022-04-08 | ツイスト バイオサイエンス コーポレーション | Ｇｌｐ１受容体の変異体核酸ライブラリ |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| AU2020298294A1 (en) | 2019-06-21 | 2022-02-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| EP4034564A4 (en) | 2019-09-23 | 2023-12-13 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES |
| US20210179724A1 (en) * | 2019-12-09 | 2021-06-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for adenosine receptors |
| WO2022082201A1 (en) * | 2020-10-16 | 2022-04-21 | Genentech, Inc. | Anti-cleaved icaspase substrate antibodies and methods of use |
| WO2022159620A1 (en) | 2021-01-21 | 2022-07-28 | Twist Bioscience Corporation | Methods and compositions relating to adenosine receptors |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| WO2024028448A1 (en) | 2022-08-04 | 2024-02-08 | Calypso Biotech Sa | Il-15 inhibitors useful for the treatment of atopic dermatitis |
| CN118894934A (zh) * | 2023-05-05 | 2024-11-05 | 北京智仁美博生物科技有限公司 | 抗人il-15的抗体及其用途 |
| CN117209605B (zh) * | 2023-11-09 | 2024-01-30 | 北京百普赛斯生物科技股份有限公司 | 特异性结合il-15的抗体及其应用 |
| WO2025227052A1 (en) | 2024-04-26 | 2025-10-30 | Cephalon Llc | Doses and formulations of anti-il-15 antibody for the treatment of immune diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| US7132510B2 (en) * | 2000-12-29 | 2006-11-07 | Bio-Technology General (Israel) Ltd. | Specific human antibodies for selective cancer therapy |
| US7329405B2 (en) * | 2001-08-23 | 2008-02-12 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
| US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
| WO2003017935A2 (en) | 2001-08-23 | 2003-03-06 | Genmab A/S | Human antibodies specific for interleukin 15 (il-15) |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| MXPA05005921A (es) | 2002-12-02 | 2005-10-19 | Abgenix Inc | Anticuerpos dirigidos a factor de necrosis tumoral y sus usos. |
| JP4892335B2 (ja) * | 2003-02-26 | 2012-03-07 | ゲンマブ エー／エス | インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体 |
| AR050293A1 (es) * | 2004-08-11 | 2006-10-11 | Moll Tomas | Polipeptidos de interleuquina-15 mutante |
| WO2006090750A1 (ja) | 2005-02-28 | 2006-08-31 | Institute For Antibodies Co., Ltd. | 抗IgSF4抗体及びその利用 |
| EP2418278A3 (en) * | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| SG182144A1 (en) | 2007-06-01 | 2012-07-30 | Omt Inc | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
| AR068767A1 (es) * | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| ES2948572T3 (es) | 2009-07-08 | 2023-09-14 | Kymab Ltd | Modelos de roedores y moléculas terapéuticas |
| AR078650A1 (es) * | 2009-10-15 | 2011-11-23 | Abbott Lab | Anticuerpo de union a il-1 beta |
| EP2550529B1 (en) * | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| US9127057B2 (en) * | 2010-07-20 | 2015-09-08 | Teva Pharmaceuticals Ausralia Pty Ltd | Anti-IL-23 heterodimer specific antibodies |
| JP5820688B2 (ja) | 2011-03-23 | 2015-11-24 | 株式会社Kri | 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法 |
| CN103890006A (zh) | 2011-08-23 | 2014-06-25 | 罗切格利卡特公司 | 抗mcsp抗体 |
| KR102096224B1 (ko) * | 2011-10-28 | 2020-04-03 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| MX2015010350A (es) * | 2013-02-26 | 2015-10-29 | Roche Glycart Ag | Moleculas de union a antigeno biespecificas que activan la celula t. |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| EP2963057A1 (en) | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
| HUE053097T2 (hu) | 2015-03-31 | 2021-06-28 | Medimmune Ltd | Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására |
| EP3472202A1 (en) | 2016-06-15 | 2019-04-24 | Amgen Inc. | Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease |
| CA3040504A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | Il15/il15ra heterodimeric fc-fusion proteins |
| AU2017382850B2 (en) | 2016-12-21 | 2024-11-21 | Cephalon Llc | Antibodies that specifically bind to human IL-15 and uses thereof |
-
2017
- 2017-12-21 AU AU2017382850A patent/AU2017382850B2/en active Active
- 2017-12-21 RS RS20250577A patent/RS66900B1/sr unknown
- 2017-12-21 LT LTEPPCT/US2017/067917T patent/LT3558369T/lt unknown
- 2017-12-21 EP EP25165676.5A patent/EP4585261A3/en active Pending
- 2017-12-21 IL IL267113A patent/IL267113B2/en unknown
- 2017-12-21 PT PT178838009T patent/PT3558369T/pt unknown
- 2017-12-21 HU HUE17883800A patent/HUE071878T2/hu unknown
- 2017-12-21 JP JP2019533652A patent/JP7155126B2/ja active Active
- 2017-12-21 PL PL17883800.9T patent/PL3558369T3/pl unknown
- 2017-12-21 WO PCT/US2017/067917 patent/WO2018119246A1/en not_active Ceased
- 2017-12-21 KR KR1020237031493A patent/KR102706743B1/ko active Active
- 2017-12-21 KR KR1020197019269A patent/KR20190097094A/ko not_active Abandoned
- 2017-12-21 BR BR112019012570A patent/BR112019012570A8/pt unknown
- 2017-12-21 CA CA3046387A patent/CA3046387A1/en active Pending
- 2017-12-21 FI FIEP17883800.9T patent/FI3558369T3/fi active
- 2017-12-21 HR HRP20250482TT patent/HRP20250482T1/hr unknown
- 2017-12-21 MD MDE20191253T patent/MD3558369T2/ro unknown
- 2017-12-21 MX MX2019007357A patent/MX2019007357A/es unknown
- 2017-12-21 MA MA47130A patent/MA47130B1/fr unknown
- 2017-12-21 EA EA201991514A patent/EA201991514A1/ru unknown
- 2017-12-21 CN CN201780079926.6A patent/CN110234349B/zh active Active
- 2017-12-21 SI SI201731602T patent/SI3558369T1/sl unknown
- 2017-12-21 UA UAA201908753A patent/UA126284C2/uk unknown
- 2017-12-21 US US16/471,616 patent/US11267883B2/en active Active
- 2017-12-21 DK DK17883800.9T patent/DK3558369T3/da active
- 2017-12-21 ES ES17883800T patent/ES3026508T3/es active Active
- 2017-12-21 AR ARP170103614A patent/AR110414A1/es unknown
- 2017-12-21 EP EP17883800.9A patent/EP3558369B1/en active Active
- 2017-12-21 PE PE2019001283A patent/PE20191497A1/es unknown
-
2019
- 2019-06-13 ZA ZA2019/03848A patent/ZA201903848B/en unknown
- 2019-06-19 MX MX2023014081A patent/MX2023014081A/es unknown
- 2019-06-20 CL CL2019001729A patent/CL2019001729A1/es unknown
- 2019-06-21 PH PH12019501453A patent/PH12019501453A1/en unknown
-
2022
- 2022-01-05 US US17/647,082 patent/US12410247B2/en active Active
- 2022-10-05 JP JP2022161059A patent/JP2022176324A/ja active Pending
-
2025
- 2025-02-20 AU AU2025201185A patent/AU2025201185A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201903848B (en) | Antibodies that specifically bind to human il-15 and uses thereof | |
| ZA201905341B (en) | Antibodies specifically binding to human il-1r7 | |
| IL266259A (en) | Antibodies to pd-1 and uses thereof | |
| IL268243A (en) | Antibodies to alpha-synuclein and their uses | |
| ZA201906813B (en) | Antibody binding specifically to muc1 and use thereof | |
| IL258332A (en) | Antibody factors specific for human differentiation group 19 and their uses | |
| ZA201808582B (en) | Antibodies to alpha-synuclein and uses thereof | |
| PT3390451T (pt) | Anticorpos humanos caninizados para il-4r alfa humano e canino | |
| ZA201901892B (en) | Antibodies that bind interleukin-2 and uses thereof | |
| IL251676A0 (en) | Antibodies that bind to ccr6 and their uses | |
| SG11201507230PA (en) | Human antibodies that bind human tnf-alpha and methods of preparing the same | |
| IL266516A (en) | An antibody that binds specifically to cd66c and its use | |
| SG11201704500VA (en) | Antibody binding to neuropilin 1 and use thereof | |
| IL269318A (en) | Antibodies to human erythroperone and uses thereof | |
| SG11202001813UA (en) | Polypeptide and antibody bound to polypeptide | |
| PL3362480T3 (pl) | Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie | |
| PT3233912T (pt) | Antocorpos que se ligam a c6 humano e utilizações destes |